- TDR and the Pooled Fund for R&D: WHO demonstration projects and CEWG follow-up
- OMB's Revised Guidance on Appointment of Lobbyists to Federal Advisory Committees, Boards, and Commissions
- Gilead's US patient access programs for Sovaldi
- Some recent cancer drug prices
- Money speaks: USTR releases letters from Congress backing PhRMA on exclusive rights biologic test data in TPP
- Gilead's MPP license for tenofovir alafenamide (TAF) patents
- Hepatitis research and development timeline
- WIPO General Assembly 2014: Hard Decisions on the Design Law Treaty and Treaty for Protection of Genetic Resources
- Hepatitis C Virus patent assignments: patents with HCV in the patent claim
- KEI Policy Brief: Non-Voluntary use of HCV patents in the United States
NFTC, a US trade association, asks USTR to sanction China for issuing and enforcing "junk patents" (2014 submission)Submitted by James Love on 9. February 2014 - 16:40
A February 7, 2014 Special 301 submission from the National Foreign Trade Council (NFTC) asks USTR to bring trade sanctions against China for granting and enforcing "junk patents." The NFTC also wants patent enforcement to be strickly a private civil remedy (Contrast to the USTR demands that countries implement linkage between drug registration and patents), and complains about China rules that would require employers to more fairly compensation the Chinese inventors they
Transcript of Bayer CEO Marjin Dekkers quote at the December 3, 2013 FT Event, regarding India compulsory license of NexavarSubmitted by Claire Cassedy on 7. February 2014 - 9:25
On January 21, 2014, Ketaki Gokhale of Bloomberg published a story in Businessweek on disputes over drug patents. The story closed with a rather sinister quote attributed to Bayer CEO Marijn Dekkers, "We did not develop this medicine for Indians.
US International Trade Commission Hearing, "Trade, Investment, and Industrial Policies in India: Effects on the US Economy"Submitted by Claire Cassedy on 6. February 2014 - 15:35
Next week, the United States International Trade Commission (ITC) will hold a two-day hearing on "Trade, Investment, and Industrial Policies in India: Effects on the US Economy." The first session will take place Wednesday, February 12, 2014 at 1:00pm and the second session will convene on Thursday, February 13, 2014 at 9:30am. Both sessions will be held at the ITC in the Main Hearing Room (room 101) at 500 E Street SW, Washington, DC.
Composition of the WIPO Coordination Committee: 83 countries invested with power to nominate the WIPO Director GeneralSubmitted by thiru on 3. February 2014 - 15:15
According to a press release issued by the World Intellectual Property Organization (WIPO) on 6 December 2013, four candidatures for the post of Director General were received before the deadline for nominations (5 PM, 6 December 2013) expired.
The WIPO press release noted that,
The candidates are (in alphabetical order of names of candidates): Mr. Francis Gurry (Australia), Mr. Geoffrey Onyeama (Nigeria), Mr. Jüri Seilenthal (Estonia), and Mr. Alfredo Suescum (Panama).
WIPO norm-setting on IP and genetic resources: will impasse on mandatory disclosure and the nature of instrument be resolved?Submitted by thiru on 3. February 2014 - 9:31
It is crunch time for WIPO's Intergovernmental Committee on Genetic Resources, Traditional Knowledge and Folklore (IGC). The 26th session meets from 3-7 February 2014 in Geneva. This week's session will focus on setting international norms for the protection of genetic resources against misappropriation and resolving two key areas of divergence: 1) the nature of the instrument and 2) the disclosure of origin requirement.
UPDATED- SCP20: Current state of play as countries clash on patents and health (WIPO Standing Committee on the Law of Patents)Submitted by thiru on 31. January 2014 - 8:39
On Friday, 31 January 2014 (6:30 PM Geneva time) the WIPO Standing Committee on the Law of Patents (SCP) resumed in plenary mode to discuss the facilitator's text (Mr. Victor Portelli, Australia) on the future work of this committee including activities on 1) Exceptions and Limitations to Patent Rights, 2) Quality of Patents, including Opposition Systems, 3) Patents and Health, 4 Confidentiality of communications between clients and their patent advisors and 5) Transfer of Technology.
20TH Session of the Standing Committee on the Law of Patents
Statement by Kenya
Agenda Item No. 8: Patents and Health, 28th January 2014
Thank you Mr. Chairman for giving Kenya the floor.
Kenya supports the statement made by Algeria on behalf of the African Group and the proposal put forward by the Group and the DAG.
KEI Intervention at SCP20 on Patents and Health
28 January 2014
Thank you Chair.
Intervention of India at EB134 expressing solidarity with the Republic of South Africa in light of PharmagateSubmitted by thiru on 27. January 2014 - 8:35
During heated discussions on the topic of access to essential medicines at the 134th session of the World Health Organization's Executive Board, India delivered the following statement on Thursday, 23 January 2014 expressing solidarity with the Republic of South Africa in light of the Pharmagate exposé.
SCP20: Opening statement of the European Union at WIPO's Standing Committee on the Law of Patents, 27 January 2014Submitted by thiru on 27. January 2014 - 8:25
On 27 January 2014, Greece, on behalf of the European Union, delivered this opening statement at the 20th session of WIPO Standing Committee on the Law of Patents (SCP). The EU's priorities for WIPO's patent committee include quality of patents (including opposition systems), work sharing and confidentiality of communication between client and their patent advisors.
With respect to limitations and exceptions to patent rights, the EU said,
Intervention of the South Centre at EB134 expressing solidarity with the Republic of South Africa (English translation)Submitted by thiru on 24. January 2014 - 10:42
This is the English translation of the intervention delivered by the South Centre on Thursday, 23 January 2014 at the 134th session of the World Health Organization's Executive Board expressing solidarity with the Government of the Republic of South Africa following the Pharmagate exposé.
Thank you, Madam President, for giving us the floor.
Three NGOs, Medicus Mundi International, HAI and MSF, each read statements during the EB discussions on the CEWG demonstration projects. The statements were limited to 300 words, and NGOs were required to provide the text 24 hours before the agenda item, and obtain WHO approval of the content. KEI worked with HAI on its statement, and the Peoples Health Movement worked with MMI on its statement. The text of the HAI and MMI statements follow:
Health Action International (HAI) statement to EB 134 On agenda item 9.3, follow up to CEWG on financing and coordination
On Thursday, 23 January 2014, Malebona Precious Matsoso (Director General of the South African National Department of Health) delivered the the following intervention at the 134th session of the World Health Organization's Executive Board under agenda item 9.7 on Access to essential medicines in response to the recent Pharmagate imbroglio.
On Thursday, 23 January 2014, the South Centre delivered the following statement at the 134th session of the World Health Organization's Executive Board under agenda item 9.7, access to essential medicines, expressing solidarity with the Government of the Republic of South Africa following the Pharmagate exposé.
GRACIAS SENORA PRESIDENTA POR DARNOS LA PALABRA.